Cover Image
市場調查報告書

AFFiRiS AG的產品平台分析

AFFiRiS AG - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224743
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
AFFiRiS AG的產品平台分析 AFFiRiS AG - Product Pipeline Review - 2016
出版日期: 2016年02月24日 內容資訊: 英文 34 Pages
簡介

AFFiRiS AG是總公司在奧地利的生物科技企業。對於需要新治療藥的慢性疾病,進行合成疫苗開發。 對於老年癡呆症、動脈粥狀硬化性心血管疾病、多系統萎縮症(MSA)、糖尿病等,以獨有的AFFITOME技術為基礎進行定做肽疫苗預防藥的開發。

本報告提供AFFiRiS AG 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

AFFiRiS AG 基本資料

  • AFFiRiS AG 概要
  • 主要資訊
  • 企業資料

AFFiRiS AG :R&D概要

  • 主要的治療範圍

AFFiRiS AG :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

AFFiRiS AG :開發中產品概況

  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

AFFiRiS AG :藥物簡介

  • AD-02
  • IMMAD-04
  • ATH-03
  • PD-01
  • PD-03
  • Vaccine for Chronic Kidney Disease
  • Vaccine for Type 2 Diabetes
  • Vaccine to Target Angiotensin II for Cardiovascular Diseases
  • Vaccine to Target PCSK9 for Atherosclerosis
  • Undisclosed Drug-1
  • Undisclosed Drug-2

AFFiRiS AG :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型

AFFiRiS AG :最近的開發平台資訊

AFFiRiS AG :開發休止的計劃

AFFiRiS AG :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07949CDB

Summary

Global Markets Direct's, 'AFFiRiS AG - Product Pipeline Review - 2016', provides an overview of the AFFiRiS AG's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AFFiRiS AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of AFFiRiS AG
  • The report provides overview of AFFiRiS AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses AFFiRiS AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features AFFiRiS AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate AFFiRiS AG's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for AFFiRiS AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding AFFiRiS AG's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AFFiRiS AG Snapshot
    • AFFiRiS AG Overview
    • Key Information
    • Key Facts
  • AFFiRiS AG - Research and Development Overview
    • Key Therapeutic Areas
  • AFFiRiS AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • AFFiRiS AG - Pipeline Products Glance
    • AFFiRiS AG - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • AFFiRiS AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • AFFiRiS AG - Drug Profiles
    • ATH-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATH-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATH-06
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PD-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PD-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AD-05
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATH-05
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PD-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Allergic Rhinitis and Asthma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Huntington's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target C5a for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target PCSK9 for Hypercholesterolemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AFFiRiS AG - Pipeline Analysis
    • AFFiRiS AG - Pipeline Products by Target
    • AFFiRiS AG - Pipeline Products by Route of Administration
    • AFFiRiS AG - Pipeline Products by Molecule Type
  • AFFiRiS AG - Recent Pipeline Updates
  • AFFiRiS AG - Dormant Projects
  • AFFiRiS AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AFFiRiS AG, Key Information
  • AFFiRiS AG, Key Facts
  • AFFiRiS AG - Pipeline by Indication, 2016
  • AFFiRiS AG - Pipeline by Stage of Development, 2016
  • AFFiRiS AG - Monotherapy Products in Pipeline, 2016
  • AFFiRiS AG - Phase I, 2016
  • AFFiRiS AG - Preclinical, 2016
  • AFFiRiS AG - Pipeline by Target, 2016
  • AFFiRiS AG - Pipeline by Route of Administration, 2016
  • AFFiRiS AG - Pipeline by Molecule Type, 2016
  • AFFiRiS AG - Recent Pipeline Updates, 2016
  • AFFiRiS AG - Dormant Developmental Projects,2016

List of Figures

  • AFFiRiS AG - Pipeline by Indication, 2016
  • AFFiRiS AG - Pipeline by Stage of Development, 2016
  • AFFiRiS AG - Monotherapy Products in Pipeline, 2016
  • AFFiRiS AG - Pipeline by Target, 2016
  • AFFiRiS AG - Pipeline by Molecule Type, 2016
Back to Top